Australia & New Zealand's Preeminent Biologics Conference

Jase is co-founder and Chief Scientific Officer of Proxima Bio, where he leads scientific strategy, pipeline development and translational research. Trained as a structural biologist and crystallographer, he has expertise in protein and antibody engineering, molecular biology and biochemistry. His work focuses on developing cell-surface degraders as a new class of biologic medicines for autoimmune and inflammatory disease.

Antiksha Joshi is a quality management professional with a deep passion for helping life science organisations implement proactive quality systems that increase regulatory compliance and improve productivity. Having worked for over 25yrs with different types of life science organisations, especially small to mid-sized, she has firsthand experience in the challenges of remaining compliant and efficient in a dynamic ecosystem. It is this experience that she brings to her consulting work - supporting companies build systems, procedures & controls that ensure continued compliance and smoother business operations.

She has helped biotech startups, manufacturing organisations and clinical trial organisations design and implement quality systems customised to their operations & compliance requirements.

Antiksha holds a Master’s in Microbiology as well as a Diploma in Counselling.

Title of the session: From Concept to Capacity: Navigating the Intersection of Innovation, Investment, and Sustainable Growth - The GPN Story

Pete Tobin is Vice President and Head of Translational Medicine at Telix, where he is establishing and leading an Australia-based translational medicine function. Previously based in Boston, Pete served as Senior Vice President, Clinical Strategy and Innovation at Telix, where he oversaw clinical development strategy across the company’s portfolio. He brings over two decades of experience collaborating with academic, clinical, and industry partners to translate novel oncology science into new treatment options for patients.

David Haylock is a stem cell biologist who jointly pioneered mobilised blood stem cell transplantation and associated mobilisation strategies and apheresis procedures that are the basis for treatments of blood cell cancers and other diseases.

Haylock developed the concept of ex vivo expansion of haemopoietic stem cells to generate cells for therapy and, as Head of Experimental Cell Therapy at the Peter MacCallum Cancer Centre in Melbourne, led Australia’s first clinical trial with GMP, ex vivo expanded CD34+ cells in the setting of repetitive high dose chemotherapy for metastatic breast cancer.

Haylock was appointed as the CSO of VivaZome Therapeutics in January 2018. In this role Haylock has developed a universal extracellular vesicle (EV) manufacturing process and a suite of analytics and potency assays for EV therapeutics.

Haylock has initiated and secured multiple collaborative partnerships with academic research groups, Australian SMEs and national and multinational biotech and pharma companies to evaluate a diverse range of technologies, materials, and assays for EV manufacture.

Paul is an established pharmaceutical/biotech CEO with over 25 years in pharmaceutical product development, operations, and business development. He holds postgraduate qualifications in Biomedical and Business studies. Paul is the current CEO of RNA Australia and has led senior roles at Pfizer and IDT Australia. Paul is recognised for driving innovation to successful commercialisation, building strong stakeholder relationships, and delivering long-term growth.

Dr Rebecca Lim is Chief Scientific Officer at INOVIQ Ltd (ASX:IIQ) with more than two decades of experience translating cell, gene and extracellular vesicle technologies from discovery through clinical development. Her career spans academic research, GMP cell therapies, early phase clinical translation, industry strategy and cross-functional program leadership. Rebecca previously held senior industry roles at CTMC (Houston, Texas) and at Monash University and the Hudson Institute of Medical Research, where she pioneered clinical translation of placental cell and exosome-based therapeutics. At INOVIQ, she leads scientific and development strategy across the company’s EV diagnostics and therapeutics programs.

Associate Professor Shayanti Mukherjee is Head of the Translational Tissue Engineering Laboratory at Hudson Institute of Medical Research and an Emerging Leader in Women’s Health. Her research integrates biomaterials, immune engineering, and regenerative medicine to develop next-generation therapies for pelvic floor disorders following childbirth injury. She leads translational programs spanning degradable surgical meshes, biological grafts and cell-derived regenerative therapies, validated across small and large animal models with a clear pathway to clinical impact. She is a recipient of the SIEF John Stocker Fellowship and Johnson & Johnson WiSTEM2D Scholar, and is a passionate advocate for equity and inclusion in STEM.

Silvio Tiziani is Chief Executive Officer of the Centre for Commercialisation of Regenerative Medicine (CCRM) Australia, where he leads initiatives focused on accelerating the translation, commercialisation and scaling of advanced therapies. With extensive international experience across biotechnology, healthcare, commercialisation and investment, he works closely with industry, researchers, governments and investors to strengthen Australia's regenerative medicine and advanced therapies ecosystem. Through CCRM Australia, Silvio is focused on building the partnerships, infrastructure and investment pathways required to support innovation, manufacturing growth and improved patient access to transformative therapies.